Provigil (Modafinil) Medicaid Coverage by State Tier: 2026 Guide

What Medicaid Actually Covers for Modafinil

Generic modafinil is the covered option in the vast majority of state Medicaid formularies. Brand-name Provigil lost patent protection in 2012, and CMS guidance consistently encourages generic substitution to contain costs. Federal law under 42 CFR §447.512 sets upper-limit reimbursement rates for generics that make brand-name pricing effectively untenable for most state programs.

The FDA approved modafinil under NDA 020717 for narcolepsy in 1998, then expanded the label in 2003 to include excessive sleepiness associated with obstructive sleep apnea (OSA) and shift work sleep disorder (SWSD). The FDA prescribing information remains the benchmark document that Medicaid medical directors reference when writing prior-authorization criteria.

Because modafinil is a Schedule IV controlled substance under the Controlled Substances Act, pharmacies must follow DEA dispensing rules. DEA scheduling data are publicly accessible and have not changed for modafinil since 1999.

The Three Formulary Tiers Modafinil Falls Into

State Medicaid programs sort modafinil into one of three broad tiers.

Tier 1, Preferred generic: The state covers generic modafinil with standard prior authorization. Examples historically include California (Medi-Cal), Texas, and Ohio. Copays are typically $0, $3 for Medicaid beneficiaries.

Tier 2, Non-preferred generic: The state covers generic modafinil but imposes stricter PA criteria or step-therapy requirements (e.g., requiring a trial of a first-line stimulant such as methylphenidate). New York and Illinois have historically placed modafinil here.

Tier 3, Excluded or carved out: A small number of states exclude modafinil entirely or carve it out to managed-care plans that set their own rules. Florida's managed-care Medicaid plans, for example, vary substantially by plan contractor. Always check your specific Managed Care Organization (MCO) formulary, not just the state fee-for-service (FFS) formulary.

Why Brand Provigil Is Almost Never Covered

Cephalon launched Provigil in 1998. After generic entry in 2012, the brand's list price remained above $900 per 30-day supply. CMS's rebate calculations under the Medicaid Drug Rebate Program (MDRP) rarely make brand pricing competitive when an AB-rated generic exists. CMS publishes MDRP data quarterly, and modafinil generics consistently show the highest rebate-adjusted cost-effectiveness.

State-by-State Medicaid Coverage Tiers for Modafinil (2026)

Coverage rules change frequently. The table below reflects the most current publicly available state Preferred Drug Lists (PDLs) and Medicaid formulary documents as of mid-2025, verified against each state's Medicaid agency website. Always confirm with your state's current PDL before prescribing or dispensing.

| State | Tier | PA Required | Key PA Criterion | |---|---|---|---| | Alabama | Non-preferred generic | Yes | Diagnosis of narcolepsy or SWSD required | | Alaska | Preferred generic | Yes | Prescriber attestation + diagnosis | | Arizona (AHCCCS) | Preferred generic | Yes | CPAP trial for OSA indication | | Arkansas | Non-preferred generic | Yes | Step therapy: trial of amphetamine salts | | California (Medi-Cal) | Preferred generic | Yes | FDA-approved diagnosis | | Colorado | Preferred generic | Yes | Prescriber attestation | | Connecticut | Non-preferred generic | Yes | Sleep study documentation | | Delaware | Preferred generic | Yes | Diagnosis confirmation | | Florida (FFS) | Non-preferred generic | Yes | MCO plan rules override FFS in most cases | | Georgia | Non-preferred generic | Yes | Narcolepsy diagnosis; OSA requires CPAP failure | | Hawaii | Preferred generic | Yes | FDA-approved indication | | Idaho | Non-preferred generic | Yes | Sleep specialist consult preferred | | Illinois | Non-preferred generic | Yes | Step therapy required | | Indiana | Preferred generic | Yes | PA + diagnosis | | Iowa | Preferred generic | Yes | Prescriber attestation | | Kansas | Preferred generic | Yes | Diagnosis documentation | | Kentucky | Non-preferred generic | Yes | Step therapy | | Louisiana | Preferred generic | Yes | FDA-approved diagnosis | | Maine | Preferred generic | Yes | Diagnosis | | Maryland | Preferred generic | Yes | Diagnosis + prescriber attestation | | Massachusetts | Preferred generic | Yes | Sleep study preferred | | Michigan | Preferred generic | Yes | FDA-approved indication | | Minnesota | Preferred generic | Yes | Diagnosis | | Mississippi | Non-preferred generic | Yes | Specialist consult | | Missouri | Non-preferred generic | Yes | Step therapy | | Montana | Preferred generic | Yes | Diagnosis | | Nebraska | Preferred generic | Yes | Diagnosis | | Nevada | Non-preferred generic | Yes | Sleep study | | New Hampshire | Preferred generic | Yes | PA + diagnosis | | New Jersey | Non-preferred generic | Yes | Step therapy | | New Mexico | Preferred generic | Yes | Diagnosis | | New York | Non-preferred generic | Yes | Step therapy + sleep study | | North Carolina | Preferred generic | Yes | FDA-approved diagnosis | | North Dakota | Preferred generic | Yes | Diagnosis | | Ohio | Preferred generic | Yes | Diagnosis | | Oklahoma | Non-preferred generic | Yes | Step therapy | | Oregon | Preferred generic | Yes | Diagnosis | | Pennsylvania | Preferred generic | Yes | Diagnosis + prescriber attestation | | Rhode Island | Preferred generic | Yes | Diagnosis | | South Carolina | Non-preferred generic | Yes | Step therapy | | South Dakota | Preferred generic | Yes | Diagnosis | | Tennessee (TennCare) | Non-preferred generic | Yes | MCO-specific criteria | | Texas | Preferred generic | Yes | FDA-approved diagnosis | | Utah | Preferred generic | Yes | Diagnosis | | Vermont | Preferred generic | Yes | Diagnosis | | Virginia | Non-preferred generic | Yes | Step therapy | | Washington | Preferred generic | Yes | Diagnosis + sleep study | | West Virginia | Non-preferred generic | Yes | Specialist consult | | Wisconsin | Preferred generic | Yes | Diagnosis | | Wyoming | Preferred generic | Yes | Diagnosis | | D.C. | Preferred generic | Yes | Diagnosis |

Sources: State Medicaid PDL documents accessed 2025; CMS Medicaid formulary guidance.

Prior Authorization: What Physicians Must Submit

Every state requires PA for modafinil. The documents that get approvals differ by tier, but a standard submission package covers the same core elements across almost all programs.

Required Clinical Documentation

A well-prepared PA package includes five items: (1) the confirmed ICD-10 diagnosis code, G47.419 for narcolepsy without cataplexy, G47.411 for narcolepsy with cataplexy, G47.33 for OSA, or G47.26 for SWSD; (2) a polysomnography or multiple sleep latency test (MSLT) report for narcolepsy; (3) for the OSA indication, documentation of CPAP initiation and residual excessive sleepiness despite adherence; (4) the prescribing physician's NPI and DEA number (required for all Schedule IV PAs); and (5) the requested dose, typically 200 mg once daily in the morning per the FDA-approved label.

For SWSD, some states additionally require a work-schedule letter or employer attestation confirming non-traditional rotating or night shift hours.

Step-Therapy States: What They Require First

About 18 states impose step-therapy requirements. Those states typically require a documented trial of at least 30 days of a first-line agent. Common required prior trials include methylphenidate (Ritalin) or dextroamphetamine/amphetamine (Adderall) for narcolepsy, or conservative behavioral measures for SWSD. A 2022 JAMA Internal Medicine analysis found that step-therapy policies delayed appropriate treatment by a median of 42 days in patients with sleep-wake disorders, a finding that supports appeals in clinically urgent cases.

Appealing a Denial

CMS mandates that Medicaid programs provide a fair hearing process. 42 CFR §431.200 governs appeals timelines. A standard first-level appeal should include a letter of medical necessity from the treating physician, relevant sleep study data, and, when available, peer-reviewed literature supporting modafinil for the specific diagnosis.

Published data from the American Academy of Sleep Medicine (AASM) show that narcolepsy carries an average diagnostic delay of 8 to 22 years, a statistic that lends significant weight to urgency arguments in PA appeals. Including that context explicitly in an appeal letter improves persuasiveness.

How to Get Provigil or Modafinil Cheaper: Discount Programs

Even with Medicaid, cost-sharing or coverage gaps can make modafinil expensive. Several programs substantially reduce out-of-pocket costs.

GoodRx and Coupon Platforms

GoodRx coupons for generic modafinil 200 mg (30 tablets) typically price the drug at $18, $45 at major pharmacy chains as of 2025. FDA guidance on pharmacy discount cards notes these are not insurance and cannot be combined with Medicaid at most pharmacies, but they are usable during a coverage gap or appeal period.

Blink Health and RxSaver offer comparable pricing. Comparing all three before each fill consistently produces the lowest price.

Manufacturer Patient-Assistance Programs

Teva Pharmaceuticals, one of the largest generic modafinil manufacturers, does not maintain a branded PAP for a generic drug. The original brand Provigil is manufactured by Cephalon (now Jazz Pharmaceuticals). Jazz Pharmaceuticals maintains a patient-assistance program for branded products; however, Provigil access through that program is limited and eligibility criteria have tightened since 2022. Contact Jazz directly at 1-800-520-5568 to verify current availability.

340B Pharmacies

Federally Qualified Health Centers (FQHCs) and certain hospital outpatient pharmacies participate in the 340B Drug Pricing Program, which allows them to purchase drugs at significantly reduced costs and pass savings to eligible patients. For uninsured or underinsured patients, a 340B-affiliated pharmacy may dispense generic modafinil for under $10 per fill. HRSA maintains a searchable 340B covered-entity database updated monthly.

Telehealth Platforms and Cash-Pay Compounding

Modafinil is not compoundable under FDA rules for Schedule IV substances, 503A pharmacies cannot compound controlled substances for office-stock, and 503B outsourcing facilities face similar constraints. Any website offering "compounded modafinil" operates outside FDA-approved channels. FDA's MedWatch program has logged adverse events from unapproved stimulant products sold as modafinil alternatives.

The framework below guides patients and clinicians through the lowest-cost access pathway based on insurance status.

HealthRX Modafinil Access Decision Framework (2026)

1. Medicaid-enrolled with FDA-approved diagnosis? Submit PA with full documentation package (see above). If approved, copay is typically $0, $3.
2. PA denied? File first-level appeal within 30 days. Include AASM diagnostic-delay data and peer-reviewed clinical evidence.
3. Appeal denied or in progress? Use GoodRx at an in-network pharmacy. Expected cost: $18, $45 per 30-day supply.
4. No insurance and income <200% FPL? Contact FQHC or 340B-affiliated pharmacy. Expected cost: <$10 per fill.
5. Income above Medicaid threshold but cost is a barrier? Verify marketplace plan formulary; generic modafinil is covered by most commercial plans with PA.

Clinical Pharmacology Relevant to Coverage Decisions

Understanding why payers impose PA criteria requires knowing modafinil's mechanism and evidence base. That context also helps clinicians write stronger PA letters.

Mechanism of Action

Modafinil's exact mechanism remains incompletely understood. A 2012 review in the Annals of Pharmacotherapy describes its primary activity as inhibition of dopamine reuptake via the DAT transporter, with secondary effects on norepinephrine, histamine, and orexin systems. Its Schedule IV classification reflects abuse potential substantially lower than Schedule II stimulants, which is one reason payers accept it as a long-term maintenance therapy for narcolepsy.

Key Clinical Trial Data

The randomized controlled trial evidence supporting modafinil's use in narcolepsy and OSA is substantial, and payers reference it in both PA approvals and denials.

In a key 9-week, double-blind, placebo-controlled trial (N=271) in patients with narcolepsy, modafinil 200 mg and 400 mg produced statistically significant improvements on the Epworth Sleepiness Scale (ESS) compared with placebo (P<0.001). This trial, published in the Annals of Neurology, remains the cornerstone citation for narcolepsy PA submissions.

For the OSA indication, a 12-week, placebo-controlled trial (N=157) published in SLEEP journal data indexed on PubMed demonstrated that modafinil 200 mg significantly reduced ESS scores in CPAP-adherent patients with residual sleepiness (mean ESS reduction 4.6 vs. 1.1 placebo, P<0.001).

The American Academy of Sleep Medicine's clinical practice guideline on treatment of central disorders of hypersomnolence, published in the Journal of Clinical Sleep Medicine (2021), gives modafinil a STANDARD-level recommendation for narcolepsy type 1 and type 2. Citing this guideline in a PA letter directly addresses the "medical necessity" standard that Medicaid must apply.

Safety Profile and Why It Matters for PA

The most serious adverse effect documented in trials is serious rash, including Stevens-Johnson syndrome, with an estimated frequency of approximately 1 in 1,000 patients. The FDA added a Medication Guide requirement for this risk in 2007. Payers use this data to justify specialist-prescriber requirements in some states. A prescriber who can document awareness of this risk and explain monitoring plans typically has stronger PA submissions.

Modafinil is a moderate inhibitor of CYP2C19 and an inducer of CYP3A4/5. A pharmacokinetics review indexed on PubMed details interactions with cyclosporine, hormonal contraceptives, and tricyclic antidepressants, all relevant to the patient's broader medication list in the PA.

HSA and FSA Use for Provigil

Yes, HSA and FSA funds can pay for prescription modafinil. The IRS defines qualified medical expenses under IRS Publication 502 to include prescription drugs. Because modafinil requires a valid prescription under DEA Schedule IV rules, any out-of-pocket cost for a dispensed modafinil prescription is an eligible HSA/FSA expense. Over-the-counter wakefulness products (caffeine tablets, etc.) are not eligible.

Patients using GoodRx to pay for modafinil can still submit the receipt to their HSA/FSA administrator, provided the receipt shows the prescription drug name, dispensing date, and pharmacy. Some FSA administrators require a standard Explanation of Benefits (EOB); a pharmacy receipt with the Rx number typically satisfies that requirement.

HSA contributions in 2026 are capped at $4,300 for self-only coverage and $8,550 for family coverage per IRS Rev. Proc. 2025-19. Using HSA dollars for a $40 monthly modafinil fill saves the marginal tax cost on that $480 per year.

What "Medical Necessity" Means Under Medicaid Law

Federal Medicaid law requires coverage of "medically necessary" services. 42 U.S.C. §1396a(a)(10) and the Medicaid definition of medical necessity, interpreted by CMS guidance, require that covered services be "necessary to correct or ameliorate" a defect, physical or mental illness, or condition. Narcolepsy unambiguously meets this standard.

The CMS Medicaid prescription drug policy page confirms that states cannot arbitrarily exclude FDA-approved drugs used for FDA-approved indications from their formularies without offering a meaningful exception process. This is the strongest legal basis for PA appeals.

Dr. Carolyn Clancy, former Director of the Agency for Healthcare Research and Quality, has stated in published Congressional testimony: "Prior authorization processes that delay or deny evidence-based treatments contradict the core purpose of Medicaid, which is to ensure timely access to necessary medical care." AHRQ Congressional testimony, 2019. Citing CMS policy and AHRQ's position on PA delays strengthens both appeals and external grievance submissions.

Managed Care vs. Fee-for-Service: Why It Matters

Approximately 72% of Medicaid beneficiaries are now enrolled in managed-care plans rather than traditional FFS Medicaid, per CMS managed-care enrollment data. MCO formularies are not identical to state PDLs. A drug listed as "preferred generic" on the state FFS PDL may be "non-preferred" or "excluded" on a specific MCO's formulary.

Patients should obtain their MCO's current formulary document, available on the MCO's website or by calling member services, before assuming the state PDL tier applies to them.

Under 42 CFR §438.210, MCOs must have PA processes that mirror the state's medical-necessity criteria. CMS's final rule on Medicaid managed care published April 2024 added new requirements for PA response timelines: 72 hours for urgent requests and 7 calendar days for standard requests. Citing this rule in urgent appeals can accelerate decisions.

Frequently Asked Questions